Use of etanercept for psoriasis in a liver transplant recipient

Madankumar, Reshmi; Teperman, Lewis; Stein, Jennifer A.

doi:10.1016/j.jdcr.2015.09.012

Cited by 19 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The pathogenesis of this post-transplantation condition is not completely understood and probably involves several factors, including a tacrolimus-induced increase in intestinal permeability, facilitating the absorption of potential allergens and promoting the development of allergy [27]. In our case study, atopic dermatitis was detected in an extremely low percentage of renal transplant recipients, i.e., in three cases out of 610 (0.5%).…”

Section: Discussionmentioning

confidence: 74%

“…This finding is consistent with a previous study [ 6 ], but in apparent contrast with the fact that most patients of our series are receiving tacrolimus, commonly used to manage seborrhoeic dermatosis [ 28 ]. A possible explanation for this paradoxical behavior could be that only a percentage of seborrhoeic patients are full responders to tacrolimus [ 28 ], similarly to those affected by psoriasis [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory Cutaneous Diseases in Renal Transplant Recipients

Savoia

Cavaliere

Zavattaro

et al. 2016

IJMS

View full text Add to dashboard Cite

Kidney transplant recipients frequently suffer from skin infections and malignancies, possibly due to the effects of long-term immunosuppressive therapy. While the relationships between immunosuppression and these pathological conditions have been widely investigated, little is known about the relative incidence and characteristics of inflammatory skin diseases in this type of patient. In this study, we analyze the incidence of a number of inflammatory cutaneous diseases in a cohort of patients who underwent kidney transplantation. Although our study shows a relatively low incidence of these pathologies in transplanted patients—in agreement with the general action of immunosuppressant therapies in reducing inflammation—we scored a different efficacy of the various immunosuppressive regimens on inflammatory and autoimmune skin diseases. This information can be key for designing immunosuppressive regimens and devising accurate follow-up protocols.

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 99%

Inflammatory Cutaneous Diseases in Renal Transplant Recipients

Savoia

Cavaliere

Zavattaro

et al. 2016

IJMS

View full text Add to dashboard Cite

show abstract

“…It may be associated with virulence genes, environmental factors, infections, and immunologic derangement ( 1 , 3 – 5 ). The main pathological characteristics are excessive keratinocyte proliferation and parakeratosis, with recurring and repeated proliferation, desquamation and inflammation in the epidermis ( 5 , 8 , 13 ). To the best of our knowledge, current treatments for PS are still limited in effect, which makes it difficult to control disease progression.…”

Section: Discussionmentioning

confidence: 99%

“…PS is believed to be an autoimmune disease (AID) with an inherited genetic predisposition, and is potentially mediated by multiple immune cells, such as dendritic cells, T cells and spongiocytes, as well as pro-inflammatory cytokines produced by these cells ( 4 , 5 ). CD8 + T cells, which represent the autoimmune core of the disease, drive the initial phase of PS and act as a repository of specific disease memory ( 4 , 6 ).…”

Section: Introductionmentioning

confidence: 99%

Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience

Zhou

Pan

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

There is currently no consensus on the most suitable therapeutic approach for psoriasis (PS) co-existing with posthepatic cirrhosis (PCs) and hepatocellular carcinoma (HCC) following liver transplantation (LT). The present study provides an analysis of the therapeutic experience of such patients. Five LT recipients (two with PC and three with HCC) with accompanying PS were included. The induction program consisted of methylprednisolone plus basiliximab treatment. The initial postoperative treatment scheme consisted of tacrolimus (FK506) plus mycophenolate mofetil (MMF) and hormone; the latter was withdrawn 1 week after LT. The patients with PC had been using FK506 with or without a postoperative MMF program; the patients with HCC and recurrence of PS had been switched to a sirolimus (SRL)-based replacement therapy. Furthermore, all patients received anti-hepatitis B virus (HBV) therapy. The patients were followed up after 8.3±1.5 years. There was a positive correlation between HBV-DNA copy numbers, and psoriatic area and severity index (PASI) scores (r=0.97; P=0.006). The PASI scores were decreased significantly at 6 months following surgery compared with pre-transplantation (P<0.05). The patients who had received the FK506-based treatment experienced PS recurrence two years post-transplantation. The PASI scores increased significantly (P<0.05) and then declined gradually, maintaining a stable level (P<0.05) by 1 year after switching to the SRL-based treatment. The patients who had received the SRL-based treatment exhibited no recurrence of PS. The results of the present study suggest that SRL therapy provides a promising novel treatment method for patients with PS following LT that may be superior to tacrolimus treatment. When co-existing HBV is present pre-transplantation, regular injection of human hepatitis B immunoglobulin should be used to prevent the HBV from relapsing or aggravating the PS.

show abstract

“…Presently, there are only five reported cases of OT PsO treated with a biologic drug and all cases received etanercept therapy (Brokalaki et al, ; Collazo, Gonzalez, & Torres, ; De Simone, Perin, Caldarola, D'Agostino, & Peris, ; Hoover, ; Madankumar, Teperman, & Stein, ). In the above five cases, all subjects responded to the etanercept treatment.…”

mentioning

confidence: 99%

Treatment of severe psoriasis with ixekizumab in a liver transplant recipient with concomitant hepatitis B virus infection

Lora

Graceffa

Felice

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Treatment of severe psoriasis (PsO) in organ transplant (OT) patients is difficult. In fact, systemic drugs used for PsO therapy can be detrimental to transplanted organs and/or can increase the risk of serious infections in subjects already taking antireject medicines. Current guidelines fail to give indications on how to manage PsO OT subjects. Moreover, only a few cases of patients with the above‐cited characteristics treated with systemic therapies have been published so far. Here, we report our experience concerning a liver transplant patient successfully treated with ixekizumab for his psoriasis throughout 1 year.

show abstract

Use of etanercept for psoriasis in a liver transplant recipient

Cited by 19 publications

References 8 publications

Inflammatory Cutaneous Diseases in Renal Transplant Recipients

Inflammatory Cutaneous Diseases in Renal Transplant Recipients

Sirolimus treatment for cirrhosis or hepatocellular carcinoma patients accompanied by psoriasis after liver transplantation: A single center experience

Treatment of severe psoriasis with ixekizumab in a liver transplant recipient with concomitant hepatitis B virus infection

Contact Info

Product

Resources

About